LONDON – The UK National Screening Committee's (UKNSC) recommendation to curtail widespread prostate cancer screening has sparked debate about equitable access to healthcare and the potential impact on vulnerable populations. While the committee cites potential harms of the prostate-specific antigen (PSA) test, concerns remain about whether this decision will exacerbate existing health disparities.

The UKNSC's conclusion that mass screening for prostate cancer is “likely to cause more harm than good” raises crucial questions about the systemic factors that contribute to prostate cancer risk and outcomes. While the recommendation includes screening for men with the BRCA2 gene variant and a family history of certain cancers, it excludes other at-risk groups, including Black men, citing “ongoing uncertainty on whether screening would cause more good than harm.” This exclusion underscores the need for more research into the unique genetic and environmental factors that affect prostate cancer risk in different populations.

The emphasis on the harms of overdiagnosis and overtreatment, leading to incontinence and erectile dysfunction, highlights the need for a more patient-centered approach to prostate cancer care. However, it also risks overlooking the experiences of men who could benefit from early detection and treatment. Critics argue that the decision prioritizes cost-effectiveness over individual patient needs and could disproportionately affect men from lower socioeconomic backgrounds who may lack access to alternative forms of preventative care.

Prof Sir Mike Richards, chair of the UKNSC, acknowledges the strong public support for prostate cancer screening but focuses on the potential harms. While his emphasis on the fact that many men with prostate cancer will live full lives without experiencing harm is valid, it does not address the underlying social determinants of health that contribute to unequal outcomes. These determinants include factors such as access to healthy food, safe housing, and quality healthcare, which disproportionately affect marginalized communities.

The UKNSC's acknowledgment that current screening methods struggle to differentiate between aggressive and non-aggressive forms of the disease underscores the need for investment in more accurate and targeted diagnostic tools. However, this investment should not come at the expense of addressing the broader social and economic factors that contribute to health inequities.